Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksEden Regulatory News (EDEN)

Share Price Information for Eden (EDEN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 4.35
Bid: 4.20
Ask: 4.50
Change: 0.10 (2.35%)
Spread: 0.30 (7.143%)
Open: 4.25
High: 4.35
Low: 4.25
Prev. Close: 4.25
EDEN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Kenya approval & first commercial-scale order

16 Nov 2015 07:00

RNS Number : 7501F
Eden Research plc
16 November 2015
 

Eden Research Plc

("Eden" or "Company")

 

Product approval in Kenya and first commercial-scale order

 

· Eden's partner, Lachlan Kenya Limited ("Lachlan"), has received approval for 3AEY in Kenya

· Kenya is the major exporter of cut flowers to the European Union supplying 38% of all cut flower imports in the EU

· The first commercial order for 3AEY has been placed with Eden

· Eden will derive revenue from product sales and royalties

 

Eden Research plc (AIM: EDEN), the AIM-listed company that provides breakthrough natural microencapsulation technologies to the global agrochemicals, animal health and consumer products industries, announces that its partner, Lachlan Kenya Limited, has received approval to commence sales of 3AEY in Kenya (where it will be sold under the trade name Hawk®). 3AEY is a fungicide formulated from plant-derived actives and a natural microencapsulation system that primarily targets Botrytis on various edible and inedible crops.

 

The approval allows Lachlan to sell 3AEY into markets in Kenya through its distribution network. Lachlan will initially be targeting the treatment of peas, beans and cucurbits (i.e. the plant family which includes cucumbers, squashes, pumpkins, courgettes and various melons) before expanding into the cut flower market for export to Europe and further afield. Kenya exports over $500 million of cut flowers each year with over 125,000 tonnes of products shipped and flown around the world, with a significant amount going to the major supermarkets in the EU.

 

Under the existing licence agreement between Eden and Lachlan, Eden is now due a milestone payment and will receive royalties based on net sales of 3AEY. Eden will also supply Lachlan with 3AEY from the UK using its network of toll manufacturers and suppliers and has received an initial order to provide enough 3AEY to treat an area of approximately 1,667 hectares.

 

Sean Smith, Chief Executive Officer of Eden, said: "The approval in Kenya, the order from Lachlan, and the subsequent sales of 3AEY are all key milestones which represent Eden's progression from being an IP development company to a commercial operation. We expect that growers, retailers and consumers will all appreciate and benefit from the safety and efficacy of our naturally-derived plant protection products. We eagerly anticipate the arrival of the first produce treated with 3AEY in the UK and the rest of Europe as an exciting milestone for Eden and our shareholders.

 

"This is the first commercial order for 3AEY which will generate product sales revenue and royalties. We expect this to be the first of many such orders not only from Kenya, but also from our other partners in Europe in due course."

 

Richard Stone-Wigg, Chief Executive Officer of Lachlan, said: "Lachlan has been working with 3AEY for a number of years and we have been very impressed with its safety profile and efficacy. Marketing trials with customers have confirmed this, and we are pleased to now be in a position to get this product into a market which is demanding zero pesticide residues, especially on exported fresh produce to Europe."

 

Eden Research plc

www.edenresearch.com

Sean Smith, Chief Executive Officer

Tel: 01993 862 761

Alex Abrey, Chief Financial Officer

Shore Capital and Corporate Limited

www.shorecap.com

Stephane Auton/Patrick Castle

Tel: 0207 408 4090

Walbrook PR Ltd

Tel: 020 7933 8780 or eden@walbrookpr.com

Paul McManus

Mob: 07980 541 893

Lianne Cawthorne

Mob: 07584 391 303

 

Notes:

 

Eden is an early stage revenue company with intellectual property and expertise in encapsulation, terpenes and environmentally friendly technologies to provide naturally occurring solutions to the global agrochemicals industry, the animal health industry, and consumer products.

 

Eden's encapsulation technology harnesses the biocidal efficacy of naturally occurring chemicals produced by plants (terpenes) and can also be used with both natural and synthetic hydrophobic compounds. The technology uses yeast cells that are a by-product of numerous commercial production processes to deliver a slow release of natural compounds for agricultural and non-agricultural uses. Terpenes are already widely used in the food flavouring, cosmetic and pharmaceutical industries.

 

Historically, terpenes have had limited commercial use in the agrochemical sector due to their volatility, phytotoxicity and poor solubility. Eden's platform encapsulation technology provides a unique, environmentally friendly solution to these problems and enables terpenes to be used as effective, low-risk agrochemicals.

 

With leading consultants in their respective fields, the Company is developing these technologies through innovative research and a series of commercial production, marketing and distribution partnerships.

 

The Company has a number of patents and a pipeline of products at differing stages of development targeting specific areas of the global agrochemicals industry. To date, the Company has invested in the region of £12m in developing and protecting its intellectual property and seeking regulatory approval for products that rely upon the Company's technologies. Revenues earned by the Company have been modest whilst the Company has concentrated on securing patent protection for its intellectual property, gaining regulatory approvals, identifying suitable industrial partners, and entering into licence agreements.

 

In May of 2013, the three actives that comprise Eden's first commercial product, 3AEY, were approved as new ingredients for use in plant protection products. This represents a major milestone in the commercialisation of Eden's technology and is a significant accomplishment for any company. To illustrate this point, one should note that in all of 2013, Eden's approvals represented 3 of only 10 new active ingredients approved by the EC.

 

Eden was admitted to trading on AIM on 11 May 2012 and trades under the symbol EDEN.

 

For more information about Eden, please visit www.edenresearch.com

 

Lachlan is a specialized marketing and distribution company in East Africa, contracted by manufacturers to promote, position and sell agricultural inputs, after technical development and registration.

 

Lachlan's vision is to source and offer unique proprietary products and services to enable customers, large and small, to benefit from advanced technologies and concepts that, through Fusion Farming, will merge the use of biologicals and botanicals with reduced toxicity pesticides and fertilizers to enable African farmers compete in a demanding world of quality, residue free food.

 

Lachlan understands that farmers need effective, robust solutions to optimize yield and therefore income and will encourage farmers to adapt new, environmentally friendly crop protection solutions and new nutritional concepts for sustainable farming, even in adverse conditions.

 

For more information on Lachlan, please visit www.lachlanafrica.com 

 

Lachlan Kenya Ltd

Sunflag Industrial Park, Mombasa Road, Godown No. 1,

P.O. Box 49470 - 00100 Nairobi, Kenya 

 

Richard Stone-Wigg Chief Executive Officer

Contact: +254 722 522 749

Email: richard.stonewigg@lachlanafrica.com

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCPKNDBOBDDCDD
Date   Source Headline
31st Jan 20247:00 amRNSBoard Change
22nd Jan 20247:00 amRNSTrading Update
19th Jan 20243:00 pmRNSHolding(s) in Company
9th Jan 20247:01 amRNSMevalone Approval in the State of California
18th Dec 20237:00 amRNSEcovelexâ„¢2023 Approval in Italy
28th Nov 20237:00 amRNSSmall Cap Virtual Investor Conference
1st Nov 20237:00 amRNSChange of Nominated Adviser and Broker
9th Oct 20234:44 pmRNSHolding(s) in Company
9th Oct 20234:39 pmRNSHolding(s) in Company
9th Oct 202312:46 pmRNSHolding(s) in Company
5th Oct 20237:00 amRNSCompletion of Conditional Placing
29th Sep 20237:01 amRNSHalf Yearly Report
29th Sep 20237:00 amRNSCapital Raising Update
31st Aug 20236:25 pmRNSGrant of Awards under Long-Term Incentive Plan
17th Aug 20239:27 amRNSResult of GM and Capital Raising update
16th Aug 20237:00 amRNSFirst Order For Ecovelex
2nd Aug 20233:22 pmRNSResult of Retail Offer
28th Jul 20235:00 pmRNSRetail Offer
28th Jul 20235:00 pmRNSPlacing and Retail Offer
3rd Jul 20237:00 amRNSRegulatory Application for Ecovelex in the UK
30th Jun 20239:17 amRNSResult of AGM
29th Jun 20237:00 amRNSAGM Statement
15th Jun 20237:00 amRNSAppointment of New Product Distributor – Colombia
9th Jun 20234:29 pmRNSHolding(s) in Company
7th Jun 20237:00 amRNSPublication of Annual Report and Notice of AGM
5th Jun 20234:47 pmRNSHolding(s) in Company
30th May 20237:00 amRNSEden and Corteva seek to bring Ecovelex to market
17th May 20237:00 amRNSExercise of Options
15th May 20237:00 amRNSMevalone authorisation in New Zealand
12th May 20237:00 amRNSRegulatory approvals in California and Florida
5th May 20237:00 amRNSPreliminary results for the year ended 31 Dec 2022
17th Apr 20237:00 amRNSRegulatory authorisation for Mevalone in Poland
23rd Mar 20237:00 amRNSUS State Regulatory Approvals Update
30th Jan 20237:00 amRNSFirst Mevalone authorisation for domestic use
10th Jan 20237:00 amRNSTrading Update
15th Dec 20222:01 pmEQSEden Research signs new Mevalone distribution deal
15th Dec 20227:00 amRNSDistribution Agreement for Mevalone in France
30th Nov 20227:00 amRNSOrganic Certification in Greece
24th Oct 202212:00 pmRNSAIM Rule 17 Notification
3rd Oct 20224:39 pmRNSHolding(s) in Company
30th Sep 20227:00 amRNSEden Half Yearly Report
28th Sep 20228:46 amRNSAppointment of Auditor
27th Sep 20225:08 pmEQSEden granted US EPA regulatory approval
26th Sep 20227:00 amRNSEden granted US EPA regulatory approval
2nd Sep 20227:00 amRNSAppointment of Non-Executive Director
22nd Aug 20227:00 amRNSTrading Update
7th Jul 20227:00 amRNSExercise of Options
29th Jun 202212:18 pmRNSResult of AGM
29th Jun 20227:00 amRNSAGM Statement
8th Jun 20227:12 amRNSNotice of AGM & Publication of Annual Report

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.